Lipopolysaccharide induces skin scarring through the TLR4/Myd88 inflammatory signaling pathway in dermal fibroblasts

MyD88 and Its Inhibitors in Cancer: Prospects and Challenges

“…Inhibitors targeting MyD88 polymorphism (ranked according to the year the inhibitor was first reported). between IL-1R and MyD88 and weakened the binding activity of NF-κB Protects the myocardium from ischaemia/reperfusion injury [92] 4210 Inhibits MyD88 dimerization Inhibits the pro-inflammatory immune signaling induced by bacterial toxins [107] Inhibits the interaction between MyD88 and IRF3/IRF7 and upregulated IFN-α Anti-viral effect [111] T6167923 Disrupts the formation of MyD88 homodimer Protects mice from toxic shock induced by SEB [105]Inhibits MyD88 expression Down-regulates the expression of Col I, Col III, and α-SMA[112] …”